Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2014

Supplementary Information-2

Copies of ¹H-NMR, ¹³C-NMR spectra and chiral HPLC chromatograms

Stereoselective Synthesis of 4-Substituted-Cyclic Sulfamidate-5-Carboxylates By Asymmetric Transfer Hydrogenation Accompanying Dynamic Kinetic Resolution and Its Use in Concise Stereoselective Synthesis of (-)-epi-Cytoxazone and Taxotere Side-Chain.

Jin-ah Kim,^a Yeon Ji Seo,^{a,b} Soyeong Kang,^{a,b} Juae Han^{a,b} and Hyeon-Kyu Lee^{a,b}*


a) Korea Chemical Banl, Korea Research Institute of Chemical Technology, PO Box 107, Yuseong, Daejeon 305-600, KOREA; b) Department of Medicinal and Pharmaceutical Chemistry, University of Science and Technology, 113 Gwahango, Yuseong, Daejeon 305-333, KOREA.


Tel: +82-42-860-7016; Fax: +82-42-860-7096 e-mail: leehk@krict.re.kr


Table of Contents


1	. ¹ H-NMR and ¹³ C-NMR spectra ······	3
	1-1. α-Hydroxy-β-keto esters ·····	4
	1-2. Cyclic imine-5-carboxylates, 6a-6t	37
	1-3. Cyclic sulfamidate-5-carboxylates, 7a-7t	77
	1-4. Methyl <i>N</i> -Boc-4-phenyl-cyclic sulfamidate-5-carboxylate, <i>N</i> -Boc- 7a ······	.117
	1-5. Isopropyl <i>N</i> -Boc-4-phenyl-cyclic sulfamidate-5-carboxylate, <i>N</i> -Boc- 7b	.121
	1-6. Benzyl <i>N</i> -Boc-4-phenyl-cyclic sulfamidate-5-carboxylate, <i>N</i> -Boc- 7c ······	.123
	1-7. Methyl <i>N</i> -Boc-4-(<i>n</i> -propyl)-cyclic sulfamidate-5-carboxylate, <i>N</i> -Boc- 7r ·······	.125
	1-8. Methyl <i>N</i> -Boc-4-cyclohexyl-cyclic sulfamidate-5-carboxylate, <i>N</i> -Boc- 7t ······	.127
	1-9. Methyl 3-phenyl-3-(<i>N</i> -Boc-amino)-2-benzoyloxy-propanoate, 8a ······	.129
	1-10. Methyl 3-(<i>N</i> -Boc-amino)-2-benzoyloxy-hexanoate, 8r ······	.131
	1-11. Methyl 3-cyclohexyl-3-(<i>N</i> -Boc-amino)-2-benzoyloxy-propanoate, 8t ······	.133
	1-12. Methyl 3-phenyl-3-(<i>N</i> -Boc-amino)-2-hydroxy-propanoate, 9a ······	.135
	1-13. 3-Phenyl-3-(<i>N</i> -Boc-amino)-2-hydroxy-propanoic acid (Taxotere side-chain), 10 ·······	.137
	1-14. N -Boc-4-(4-Methoxy-phenyl)-5-methoxycarbonyl-cyclic sulfamidate, N -Boc-7 \mathbf{j} · · · · · · · · · · · · · · · · · · ·	.139
	1-15. Methyl 3-(4-methoxy-phenyl)-3-(<i>N</i> -Boc-amino)-2-benzoyloxy-propanoate, 8j ··········	.141
	1-16. Methyl 3-(4-methoxy-phenyl)-3-(<i>N</i> -Boc-amino)-2-hydroxy-propanoate, 9j ······	.143
	1-17. 3-(4-Methoxy-phenyl)-3-(<i>N</i> -Boc-amino)-propan-1,2-diol, 11 ···································	.145
	1-18. (-)-epi-Cytoxazone, 12	.147
2	. Chiral HPLC Chromatograms ······	.149
	2-1. Cyclic sulfamidate-5-carboxylates, 7a , 7d-7q , 7s ······	.150
	2-2. Methyl <i>N</i> -Boc-4-phenyl-cyclic sulfamidate-5-carboxylate, (<i>S,S</i>)- <i>N</i> -Boc- 7a ····································	·152
	2-3. Methyl <i>N</i> -Boc-4-phenyl-cyclic sulfamidate-5-carboxylate, (<i>R</i> , <i>R</i>)- <i>N</i> -Boc- 7a ·······	.153
	2-4. Isopropyl N -Boc-4-phenyl-cyclic sulfamidate-5-carboxylate, (S , S)- N -Boc- 7b · · · · · · · · · · · · · · · · · · ·	.154
	2-5. Benzyl N -Boc-4-phenyl-cyclic sulfamidate-5-carboxylate, (S , S)- N -Boc-7 \mathbf{c} · · · · · · · · · · · · · · · · · · ·	.155
	2-6. Methyl 3-(<i>N</i> -Boc-amino)-2-benzoyloxy-hexanoate, (2 <i>R</i> ,3 <i>S</i>)- 8r ····································	.172
	2-7. Methyl 3-cyclohexyl-3-(<i>N</i> -Boc-amino)-2-benzoyloxy-propanoate, (2 <i>R</i> ,3 <i>S</i>)-8t ······	.173


¹H-NMR and ¹³C-NMR spectra

















































































































































































































































































































































































































































Chiral HPLC Chromatograms

Chiral HPLC Chromatograms of ATH-DKR products

Sample name: (S,S)-7a

▶ Analysis condition: Chiralpak IB, 20% EtOH/n-hexane, 1.0 ml/min, 215nm





► Result Report


Time [min]

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	10.7000	550.3260	ŦŦ	40.0000	1.4940
2	12.8667	36285.7819	44	114.0000	98.5060
합계		36836.1094			

ee=97%

Sample name: (R,R)-7a

▶ Analysis condition: Chiralpak IB, 20% EtOH/n-hexane, 1.0 ml/min, 215nm




► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	9.8500	22019.3878	FF	109.0000	99.0959
2	13.7000	200.8943	ŦŦ	42.0000	0.9041
합계		22220.2832			

ee=98%

► Sample name: (S,S)-N-Boc-7a

▶ Analysis condition: Chiralpak AD-H, 10% iPrOH/n-hexane, 1.0 ml/min, 215nm



► Result Report


Peak#	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	9.2333	347.1643	FF	32.0000	1.0986
2	13.4167	31252.2745	BB	96.0000	98.9014
Total		31599.4395			

Time [min]

ee=98%

► Sample name: (R,R)-N-Boc-7a

▶ Analysis condition: Chiralpak AD-H, 10% iPrOH/n-hexane, 1.0 ml/min, 215nm




▶ Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	9.2833	2362.1962	BB	62.0000	98.8747
2	13.8333	26.8841	FF	43.0000	1.1253
Total		2389.0803	_		

ee=98%

▶ Sample name: (S,S)-N-Boc-**7b**

▶ Analysis condition: Chiralpak AD-H, 10% iPrOH/n-hexane, 1.0 ml/min, 215nm




► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	9.7000	351.3224	BB	43.0000	1.0484
2	14.2833	32805.7090	BB	118.0000	97.8995
Total		33510.9453			

ee=97.2%

▶ Sample name: (S,S)-N-Boc-7c

▶ Analysis condition: Chiralpak AD-H, 10% iPrOH/n-hexane, 1.0 ml/min, 215nm




► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	18.5667	387.5644	BB	68.0000	1.0268
2	22.1667	37040.3066	BB	168.0000	98.1286
Total		37746.6836			

ee=97.9%

Sample name: (S,S)-7d

▶ Analysis condition: Chiralpak AD-H, 5% iPrOH/n-hexane, 1.0 ml/min, 215nm






► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	32.2667	28.7343	BB	42.0000	0.0730
2	36.2500	39153.5218	BB	208.0000	99.4094
Total		39182.2561			

ee=>99%

Sample name: (S,S)-7e

▶ Analysis condition: Chiralpak AD-H, 20% iPrOH/n-hexane, 1.0 ml/min, 215nm






► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	8.4333	15569.3232	BB	63.0000	96.0666
2	10.1000	637.4800	FF	40.0000	3.9334
Total		16206.8037			

ee=92.1%

Sample name: (S,S)-7**f**

▶ Analysis condition: Chiralpak AD-H, 10% iPrOH/n-hexane, 1.3 ml/min, 215nm






► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	15.9667	196.3357	ŦŦ	43.0000	0.6009
2	17.0000	32476.0723	FF	93.0000	99.3991
Total		32672.4082			

ee=98.7%

Sample name: (S,S) -7g

▶ Analysis condition: Chiralpak AD-H, 20% iPrOH/n-hexane, 1.0 ml/min, 215nm






► Result Report


Peak #	Time[min]	Area[mV*s]	$_{ m BL}$	wide[sec]	Area%
1	10.1167	4504.8323	FF	67.0000	99.5876
2	12.4833	18.6563	ŦŦ	27.0000	0.4124
Total		4523.4888			

ee=99.2%

Sample name: (S,S) -7h

▶ Analysis condition: Chiralpak AD-H, 10% iPrOH/n-hexane, 1.2 ml/min, 215nm






► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	13.8333	156.0047	FF	40.0000	1.6030
2	15.0333	9576.3127	FF	80.0000	98.3970
Total		9732.3174			

ee=96.7%

Sample name: (S,S)-7i

▶ Analysis condition: Chiralpak AD-H, 10% EtOH/n-hexane, 1.5 ml/min, 215nm




► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	9.2667	110.8649	FF	33.0000	1.3545
2	14.0667	8073.8913	FF	85.0000	98.6455
Total		8184.7563			

ee=97.3%

Sample name: (S,S)-7**j**

▶ Analysis condition: Chiralpak AD-H, 20% iPrOH/n-hexane, 1.0 ml/min, 215nm



19,9681 Time [min]

(*S,S*)-7j


► Result Report

Peak#	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	14.0000	2420.6589	FF	72.0000	100.0000
Total					100.0000

ee=>99%

Sample name: (S,S)-7k

▶ Analysis condition: Chiralpak IA, 20% EtOH/n-hexane, 1.0 ml/min, 215nm




► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	12.5333	402.7184	FF	41.0000	1.3427
2	16.1500	29590.0409	FF	100.0000	98.6573
Total		29992.7598			

ee=97.3%

Sample name: (S,S)-71

▶ Analysis condition: Chiralpak IA, 20% EtOH/n-hexane, 1.5 ml/min, 215nm




► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	6.5000	16.5963	FF	24.0000	0.2520
2	10.8333	6569.2955	FF	74.0000	99.7480
Total		6585.8921			

ee=98.5%

Sample name: (S,S)-7m

▶ Analysis condition: Chiralpak IA, 30% EtOH/n-hexane, 1.3 ml/min, 215nm




► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	9.2167	351.4940	FF	46.0000	1.8410
2	13.7667	18740.6826	FF	81.0000	98.1590
Total		19092.1758			

ee=96.3%

Sample name: (S,S)-7n

▶ Analysis condition: Chiralpak IA, 20% EtOH/n-hexane, 1.5 ml/min, 215nm






► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	12.0000	129.7953	FF	41.0000	1.6647
2	13.9833	7666.9291	BB	97.0000	98.3353
Total		7796.7246			

ee=96.7%

Sample name: (S,S) -70

▶ Analysis condition: Chiralpak AD-H, 20% iprOH/n-hexane, 1.0 ml/min, 215nm






► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	11.5333	24396.7379	FF	69.0000	98.3557
2	13.7333	407.8611	FF	41.0000	1.6443
Total		24804.5996			

ee=96.7%

Sample name: (S,S) -7p

▶ Analysis condition: Chiralpak IA, 20% EtOH/n-hexane, 1.5 ml/min, 215nm




► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	8.6833	1230.3090	ŦŦ	60.0000	97.4679
2	14.3333	31.9625	FF	48.0000	2.5321
Total		1262.2714			

ee=94.9%

► Sample name: (R,R)-7p

▶ Analysis condition: Chiralpak IA, 20% EtOH/n-hexane, 1.5 ml/min, 215nm






► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	8.6167	213.4351	FF	39.0000	2.3101
2	14.2833	9025.6053	BB	99.0000	97.6899
Total		9239.0400			

ee=95.3%

Sample name: (S,S)-7q

▶ Analysis condition: Chiralpak IA, 20% EtOH/n-hexane, 1.5 ml/min, 215nm






► Result Report

Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	12.5000	47.0973	FF	36.0000	0.6703
2	14.2167	6979.5146	FF	100.0000	99.3297
Total		7026.6118			

ee=98.7%

Sample name: (S,S)-7s

▶ Analysis condition: Chiralpak IA, 20% EtOH/n-hexane, 1.5 ml/min, 215nm




► Result Report


Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	6.0000	302.5704	FF	25.0000	11.9138
2	7.9500	2237.1001	FF	43.0000	88.0862
Total		2539.6707			

ee=76.1%

► Sample name: (2R,3S)-8r

▶ Analysis condition: Chiralpak IC, 10% iPrOH/n-hexane, 0.7 ml/min, 254nm






Peak #	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	9.2667	185.5496	BB	38.0000	4.3399
2	11.1500	4089.8949	BB	28.0000	95.6601
Total		4275.4443			

ee=91.3%

Sample name: (2R,3S)-8t

▶ Analysis condition: Chiralpak IC, 10% iPrOH/n-hexane, 0.7 ml/min, 254nm



Peak#	Time[min]	Area[mV*s]	BL	wide[sec]	Area%
1	8.3500	832.8883	BB	46.0000	26.2840
2	9.5500	2335.9153	BB	68.0000	73.7160
Total		3168.8035			

ee=47.4%